The first non-brand replica drug Zarxio by Sandoz is approved in FDA history

March 8, 2015 2:33 AM

15 0

The US Food and Drug Administration (FDA) have approved the first non-brand name version of a biological drug called Zarxio. This drug facilitates patients to raise the level white blood cells after these cells have been obliterated by chemotherapy.

Zarxio is a manufacturer by Sandoz and this drug is a cheaper replica or biosimilar version of Amgen’s biologic drug Neupogen. In 1991, the FDA had approved the manufacturing of Neupogen, commonly acknowledged as Filgratism.

Read more

To category page